Lisofylline

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Lisofylline
Accession Number
DB12406
Type
Small Molecule
Groups
Investigational
Description

Lisofylline has been investigated for the treatment of Type 1 Diabetes Mellitus.

Structure
Thumb
Synonyms
Not Available
External IDs
CT 1501R
Categories
UNII
L1F2Q2X956
CAS number
100324-81-0
Weight
Average: 280.328
Monoisotopic: 280.15354052
Chemical Formula
C13H20N4O3
InChI Key
NSMXQKNUPPXBRG-SECBINFHSA-N
InChI
InChI=1S/C13H20N4O3/c1-9(18)6-4-5-7-17-12(19)10-11(14-8-15(10)2)16(3)13(17)20/h8-9,18H,4-7H2,1-3H3/t9-/m1/s1
IUPAC Name
1-[(5R)-5-hydroxyhexyl]-3,7-dimethyl-2,3,6,7-tetrahydro-1H-purine-2,6-dione
SMILES
C[[email protected]@H](O)CCCCN1C(=O)N(C)C2=C(N(C)C=N2)C1=O

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Lisofylline is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Lisofylline is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Lisofylline is combined with 5-androstenedione.Experimental, Illicit
AbciximabLisofylline may increase the anticoagulant activities of Abciximab.Approved
AcebutololLisofylline may decrease the antihypertensive activities of Acebutolol.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Lisofylline.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Lisofylline is combined with Acemetacin.Approved
AcenocoumarolLisofylline may increase the anticoagulant activities of Acenocoumarol.Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Lisofylline.Approved, Vet Approved
AclarubicinLisofylline may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Lisofylline.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Lisofylline is combined with Alclofenac.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Lisofylline is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Lisofylline is combined with Aldosterone.Experimental, Investigational
Alendronic acidThe risk or severity of adverse effects can be increased when Lisofylline is combined with Alendronic acid.Approved
AliskirenLisofylline may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Lisofylline is combined with Alminoprofen.Experimental
AlprenololLisofylline may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Lisofylline.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Lisofylline is combined with Amcinonide.Approved
AmikacinLisofylline may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Vet Approved
AmilorideLisofylline may decrease the antihypertensive activities of Amiloride.Approved
AmrubicinLisofylline may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AncrodLisofylline may increase the anticoagulant activities of Ancrod.Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Lisofylline.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Lisofylline is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Lisofylline is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when Lisofylline is combined with anecortave acetate.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Lisofylline.Investigational
annamycinLisofylline may decrease the excretion rate of annamycin which could result in a higher serum level.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Lisofylline.Approved
Antithrombin III humanLisofylline may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanLisofylline may increase the anticoagulant activities of Apixaban.Approved
ApocyninThe risk or severity of adverse effects can be increased when Lisofylline is combined with Apocynin.Investigational
ApramycinLisofylline may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Lisofylline.Approved, Investigational
ArbekacinLisofylline may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Investigational
ArdeparinLisofylline may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanLisofylline may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololLisofylline may decrease the antihypertensive activities of Arotinolol.Approved, Investigational
AtamestaneThe risk or severity of adverse effects can be increased when Lisofylline is combined with Atamestane.Investigational
AtenololLisofylline may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Lisofylline.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Lisofylline.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Lisofylline.Approved
BalsalazideLisofylline may increase the nephrotoxic activities of Balsalazide.Approved, Investigational
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Lisofylline.Investigational
BecaplerminLisofylline may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Lisofylline is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololLisofylline may decrease the antihypertensive activities of Befunolol.Experimental
BekanamycinLisofylline may decrease the excretion rate of Bekanamycin which could result in a higher serum level.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Lisofylline.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Lisofylline is combined with Bendazac.Experimental
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Lisofylline.Approved
BenorilateThe risk or severity of adverse effects can be increased when Lisofylline is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Lisofylline.Withdrawn
BenzydamineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Benzydamine.Approved
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Lisofylline.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Lisofylline is combined with Betamethasone.Approved, Vet Approved
BetaxololLisofylline may decrease the antihypertensive activities of Betaxolol.Approved
BevantololLisofylline may decrease the antihypertensive activities of Bevantolol.Approved
BevoniumThe risk or severity of adverse effects can be increased when Lisofylline is combined with Bevonium.Experimental
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Lisofylline.Approved, Investigational
BisoprololLisofylline may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinLisofylline may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololLisofylline may decrease the antihypertensive activities of Bopindolol.Approved
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Lisofylline.Approved
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Lisofylline.Investigational
BucindololLisofylline may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Lisofylline is combined with Budesonide.Approved
BufexamacThe risk or severity of adverse effects can be increased when Lisofylline is combined with Bufexamac.Experimental
BufuralolLisofylline may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumadizoneThe risk or severity of adverse effects can be increased when Lisofylline is combined with Bumadizone.Experimental
BumetanideLisofylline may decrease the diuretic activities of Bumetanide.Approved
BupranololLisofylline may decrease the antihypertensive activities of Bupranolol.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Lisofylline.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Lisofylline.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Lisofylline.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Lisofylline.Approved
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Lisofylline.Approved
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Lisofylline.Approved, Vet Approved, Withdrawn
CarteololLisofylline may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolLisofylline may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Lisofylline.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Lisofylline.Approved, Investigational
CeliprololLisofylline may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CertoparinLisofylline may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Lisofylline.Approved, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Lisofylline.Approved, Vet Approved
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Lisofylline.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Lisofylline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Lisofylline.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Lisofylline is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Lisofylline.Approved
CinoxacinLisofylline may increase the neuroexcitatory activities of Cinoxacin.Approved, Investigational, Withdrawn
Citric AcidLisofylline may increase the anticoagulant activities of Citric Acid.Approved, Nutraceutical, Vet Approved
ClobetasolThe risk or severity of adverse effects can be increased when Lisofylline is combined with Clobetasol.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Lisofylline is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Lisofylline is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Lisofylline is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Lisofylline is combined with Clodronic Acid.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Lisofylline.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Lisofylline.Vet Approved
CloranololLisofylline may decrease the antihypertensive activities of Cloranolol.Experimental
Clostridium tetani toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Lisofylline.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Lisofylline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Lisofylline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Lisofylline is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Lisofylline is combined with Corticosterone.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Lisofylline is combined with Cortisone acetate.Approved
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Lisofylline.Approved
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Lisofylline.Investigational
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Lisofylline.Experimental
CyclosporineLisofylline may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
D-LimoneneThe risk or severity of adverse effects can be increased when D-Limonene is combined with Lisofylline.Investigational
Dabigatran etexilateLisofylline may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinLisofylline may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidLisofylline may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarexabanLisofylline may increase the anticoagulant activities of Darexaban.Investigational
DaunorubicinLisofylline may decrease the excretion rate of Daunorubicin which could result in a higher serum level.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Lisofylline is combined with Deferasirox.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Lisofylline is combined with Deflazacort.Approved
DelaprilThe risk or severity of adverse effects can be increased when Delapril is combined with Lisofylline.Experimental
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Lisofylline.Approved
DesirudinLisofylline may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Lisofylline is combined with Desmopressin.Approved
DesonideThe risk or severity of adverse effects can be increased when Lisofylline is combined with Desonide.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Lisofylline is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Lisofylline is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Lisofylline is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Lisofylline is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Lisofylline is combined with Dexamethasone isonicotinate.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Lisofylline.Approved, Investigational
DextranLisofylline may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Lisofylline may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Lisofylline may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Lisofylline may increase the anticoagulant activities of Dextran 75.Approved
DibekacinLisofylline may decrease the excretion rate of Dibekacin which could result in a higher serum level.Experimental
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Lisofylline.Approved, Vet Approved
DicoumarolLisofylline may increase the anticoagulant activities of Dicoumarol.Approved
DifenpiramideThe risk or severity of adverse effects can be increased when Lisofylline is combined with Difenpiramide.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Lisofylline is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Lisofylline.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Lisofylline is combined with Difluocortolone.Approved, Investigational
DifluprednateThe risk or severity of adverse effects can be increased when Lisofylline is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Lisofylline.Approved
DihydrostreptomycinLisofylline may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational, Vet Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Lisofylline.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Lisofylline.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Lisofylline.Approved
DoxorubicinLisofylline may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
DrospirenoneLisofylline may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Lisofylline.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Lisofylline.Investigational
E-6201The risk or severity of adverse effects can be increased when E-6201 is combined with Lisofylline.Investigational
Edetic AcidLisofylline may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanLisofylline may increase the anticoagulant activities of Edoxaban.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Lisofylline.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Lisofylline.Approved
EnoxacinLisofylline may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
EnoxaparinLisofylline may increase the anticoagulant activities of Enoxaparin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with Lisofylline.Experimental
EpanololLisofylline may decrease the antihypertensive activities of Epanolol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Lisofylline.Approved
EpirubicinLisofylline may decrease the excretion rate of Epirubicin which could result in a higher serum level.Approved
EplerenoneLisofylline may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Lisofylline.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Lisofylline.Approved
EquileninThe risk or severity of adverse effects can be increased when Lisofylline is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Lisofylline is combined with Equilin.Approved
EsmololLisofylline may decrease the antihypertensive activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when Lisofylline is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Lisofylline is combined with Estrone sulfate.Approved
Etacrynic acidLisofylline may decrease the diuretic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Lisofylline.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Lisofylline is combined with Ethenzamide.Experimental
Ethyl biscoumacetateLisofylline may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Lisofylline is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Lisofylline.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Lisofylline.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Lisofylline.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Lisofylline.Approved, Investigational
exisulindThe risk or severity of adverse effects can be increased when exisulind is combined with Lisofylline.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Lisofylline.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Lisofylline.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Lisofylline.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Lisofylline.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Lisofylline is combined with Fentiazac.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Lisofylline is combined with Feprazone.Experimental
Ferulic acidLisofylline may increase the anticoagulant activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Lisofylline.Approved, Investigational
FingolimodLisofylline may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
FleroxacinLisofylline may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Lisofylline.Approved, Withdrawn
fluasteroneThe risk or severity of adverse effects can be increased when Lisofylline is combined with fluasterone.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Lisofylline is combined with Fludrocortisone.Approved
FluindioneLisofylline may increase the anticoagulant activities of Fluindione.Investigational
FlumequineLisofylline may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Lisofylline is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Lisofylline is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Lisofylline.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Lisofylline is combined with Flunoxaprofen.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Lisofylline is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Lisofylline is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Lisofylline is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Lisofylline is combined with Fluorometholone.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Lisofylline is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Lisofylline is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Lisofylline.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Lisofylline is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Lisofylline.Approved, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Lisofylline is combined with Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Lisofylline is combined with Fluticasone propionate.Approved
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Lisofylline.Approved, Nutraceutical, Vet Approved
FondaparinuxLisofylline may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumLisofylline may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Lisofylline.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Lisofylline is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Lisofylline.Approved
FramycetinLisofylline may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideLisofylline may decrease the diuretic activities of Furosemide.Approved, Vet Approved
G17DTThe therapeutic efficacy of G17DT can be decreased when used in combination with Lisofylline.Investigational
GabexateLisofylline may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinLisofylline may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinLisofylline may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Lisofylline.Approved, Withdrawn
GemifloxacinLisofylline may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinLisofylline may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinLisofylline may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1ALisofylline may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GI-5005The therapeutic efficacy of GI-5005 can be decreased when used in combination with Lisofylline.Investigational
GPX-150Lisofylline may decrease the excretion rate of GPX-150 which could result in a higher serum level.Investigational
GrepafloxacinLisofylline may increase the neuroexcitatory activities of Grepafloxacin.Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Lisofylline is combined with Guacetisal.Experimental
HalcinonideThe risk or severity of adverse effects can be increased when Lisofylline is combined with Halcinonide.Approved, Investigational, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Lisofylline is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Lisofylline is combined with HE3286.Investigational
HeparinLisofylline may increase the anticoagulant activities of Heparin.Approved, Investigational
Hepatitis A VaccineThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Lisofylline.Approved
Hepatitis B Vaccine (Recombinant)The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Lisofylline.Approved, Withdrawn
HigenamineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Higenamine.Investigational
HydralazineLisofylline may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Lisofylline.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Lisofylline is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Lisofylline.Approved, Investigational
Hygromycin BLisofylline may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Lisofylline is combined with Ibandronate.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Lisofylline.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Lisofylline.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Lisofylline.Approved
IdarubicinLisofylline may decrease the excretion rate of Idarubicin which could result in a higher serum level.Approved
IdraparinuxLisofylline may increase the anticoagulant activities of Idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Lisofylline.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Lisofylline.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Lisofylline is combined with Imidazole salicylate.Experimental
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Lisofylline.Approved
IndenololLisofylline may decrease the antihypertensive activities of Indenolol.Withdrawn
IndobufenThe risk or severity of adverse effects can be increased when Lisofylline is combined with Indobufen.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Lisofylline.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Lisofylline.Withdrawn
INGN 201The therapeutic efficacy of INGN 201 can be decreased when used in combination with Lisofylline.Investigational
INGN 225The therapeutic efficacy of INGN 225 can be decreased when used in combination with Lisofylline.Investigational
INNO-206Lisofylline may decrease the excretion rate of INNO-206 which could result in a higher serum level.Investigational
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Lisofylline.Approved, Investigational
IsepamicinLisofylline may decrease the excretion rate of Isepamicin which could result in a higher serum level.Experimental
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Lisofylline.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Lisofylline is combined with Istaroxime.Investigational
KanamycinLisofylline may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Investigational, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Lisofylline.Experimental
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Lisofylline.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Lisofylline.Approved
LabetalolLisofylline may decrease the antihypertensive activities of Labetalol.Approved
LandiololLisofylline may decrease the antihypertensive activities of Landiolol.Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Lisofylline.Approved, Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Lisofylline.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Lisofylline is combined with Leflunomide.Approved, Investigational
LepirudinLisofylline may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanLisofylline may increase the anticoagulant activities of Letaxaban.Investigational
LevobunololLisofylline may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinLisofylline may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Lisofylline.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Lisofylline.Approved, Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Lisofylline.Approved
LonazolacThe risk or severity of adverse effects can be increased when Lisofylline is combined with Lonazolac.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Lisofylline.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Lisofylline.Approved
LoteprednolThe risk or severity of adverse effects can be increased when Lisofylline is combined with Loteprednol.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Lisofylline.Approved, Investigational
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Lisofylline.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Lisofylline.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Lisofylline.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Lisofylline.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Lisofylline.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when Lisofylline is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Lisofylline.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Lisofylline is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Lisofylline.Approved
MelagatranLisofylline may increase the anticoagulant activities of Melagatran.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when Lisofylline is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Lisofylline.Approved, Vet Approved
MepindololLisofylline may decrease the antihypertensive activities of Mepindolol.Experimental
MesalazineLisofylline may increase the nephrotoxic activities of Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Lisofylline.Investigational, Withdrawn
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Lisofylline.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Lisofylline.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Lisofylline is combined with Methylprednisolone.Approved, Vet Approved
MetipranololLisofylline may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Lisofylline.Approved
MetoprololLisofylline may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MetrizamideLisofylline may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MicronomicinLisofylline may decrease the excretion rate of Micronomicin which could result in a higher serum level.Experimental
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Lisofylline.Approved
MizoribineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Mizoribine.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Lisofylline.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Lisofylline is combined with Mofebutazone.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Lisofylline is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Lisofylline.Approved
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Lisofylline.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Lisofylline.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Lisofylline.Approved
NadololLisofylline may decrease the antihypertensive activities of Nadolol.Approved
NadroparinLisofylline may increase the anticoagulant activities of Nadroparin.Approved
NafamostatLisofylline may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Lisofylline.Approved
Nalidixic AcidLisofylline may increase the neuroexcitatory activities of Nalidixic Acid.Approved, Investigational
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Lisofylline.Approved, Vet Approved
NatalizumabThe risk or severity of adverse effects can be increased when Lisofylline is combined with Natalizumab.Approved, Investigational
NCX 1022The risk or severity of adverse effects can be increased when Lisofylline is combined with NCX 1022.Investigational
NeamineLisofylline may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NebivololLisofylline may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
NemonoxacinLisofylline may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinLisofylline may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Lisofylline.Approved
NetilmicinLisofylline may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Lisofylline is combined with Nifenazone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Lisofylline.Approved
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Lisofylline.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Lisofylline is combined with Nitroaspirin.Investigational
NorfloxacinLisofylline may increase the neuroexcitatory activities of Norfloxacin.Approved
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Lisofylline is combined with Oleoyl-estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Lisofylline.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Lisofylline.Approved
OlsalazineLisofylline may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Lisofylline is combined with Omacetaxine mepesuccinate.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Lisofylline.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Lisofylline.Vet Approved
OtamixabanLisofylline may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Lisofylline.Approved
Oxolinic acidLisofylline may increase the neuroexcitatory activities of Oxolinic acid.Experimental
OxprenololLisofylline may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Lisofylline.Approved, Withdrawn
PamidronateThe risk or severity of adverse effects can be increased when Lisofylline is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Lisofylline is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Lisofylline.Approved
ParomomycinLisofylline may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Lisofylline is combined with Parthenolide.Investigational
PazufloxacinLisofylline may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinLisofylline may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololLisofylline may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentaerythritol TetranitrateLisofylline may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
Pentosan PolysulfateLisofylline may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Lisofylline.Approved
PhenindioneLisofylline may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonLisofylline may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Lisofylline.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Lisofylline.Approved, Investigational
PindololLisofylline may decrease the antihypertensive activities of Pindolol.Approved
Pipemidic acidLisofylline may increase the neuroexcitatory activities of Pipemidic acid.Experimental
PirarubicinLisofylline may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PiretanideLisofylline may decrease the diuretic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Lisofylline.Approved, Investigational
Piromidic acidLisofylline may increase the neuroexcitatory activities of Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Lisofylline.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Lisofylline is combined with Pirprofen.Experimental
Platelet Activating FactorLisofylline may decrease the antihypertensive activities of Platelet Activating Factor.Experimental
PlazomicinLisofylline may decrease the excretion rate of Plazomicin which could result in a higher serum level.Investigational
PlicamycinLisofylline may decrease the excretion rate of Plicamycin which could result in a higher serum level.Approved, Investigational, Withdrawn
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Lisofylline.Approved
PractololLisofylline may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Lisofylline.Approved
PranoprofenThe risk or severity of adverse effects can be increased when Lisofylline is combined with Pranoprofen.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Lisofylline is combined with Prasterone.Approved, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Lisofylline is combined with Prasterone sulfate.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Lisofylline is combined with Prednicarbate.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Lisofylline is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Lisofylline is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Lisofylline is combined with Pregnenolone.Experimental, Investigational
ProbenecidThe serum concentration of Lisofylline can be increased when it is combined with Probenecid.Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Lisofylline is combined with Proglumetacin.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Lisofylline.Approved, Investigational
PropranololLisofylline may decrease the antihypertensive activities of Propranolol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Lisofylline is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Lisofylline is combined with Proquazone.Experimental
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Lisofylline.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Lisofylline.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Lisofylline.Vet Approved
Protein CLisofylline may increase the anticoagulant activities of Protein C.Approved
Protein S humanLisofylline may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeLisofylline may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinLisofylline may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Lisofylline.Investigational
PuromycinLisofylline may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Lisofylline.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Lisofylline.Approved
Rabies virus inactivated antigen, AThe risk or severity of adverse effects can be increased when Lisofylline is combined with Rabies virus inactivated antigen, A.Approved
Rabies virus inactivated antigen, AThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Lisofylline.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Lisofylline.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Lisofylline.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Lisofylline.Approved, Experimental, Investigational
ReviparinLisofylline may increase the anticoagulant activities of Reviparin.Approved, Investigational
RibostamycinLisofylline may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Lisofylline is combined with Rimexolone.Approved
RindopepimutThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Lisofylline.Investigational
RisedronateThe risk or severity of adverse effects can be increased when Lisofylline is combined with Risedronate.Approved, Investigational
RivaroxabanLisofylline may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Lisofylline.Investigational, Withdrawn
RoflumilastRoflumilast may increase the immunosuppressive activities of Lisofylline.Approved
RosoxacinLisofylline may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
Rotavirus VaccineThe therapeutic efficacy of Rotavirus Vaccine can be decreased when used in combination with Lisofylline.Approved
Rubella virus vaccineThe therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Lisofylline.Approved
RufloxacinLisofylline may increase the neuroexcitatory activities of Rufloxacin.Experimental
SabarubicinLisofylline may decrease the excretion rate of Sabarubicin which could result in a higher serum level.Investigational
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Lisofylline.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Lisofylline.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Lisofylline.Approved, Vet Approved
Salmonella typhi ty21a live antigenThe therapeutic efficacy of Salmonella typhi ty21a live antigen can be decreased when used in combination with Lisofylline.Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Lisofylline.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Lisofylline.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Lisofylline.Investigational
SemapimodThe risk or severity of adverse effects can be increased when Semapimod is combined with Lisofylline.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Lisofylline.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Lisofylline is combined with Serrapeptase.Investigational
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Lisofylline.Approved
SisomicinLisofylline may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SitafloxacinLisofylline may increase the neuroexcitatory activities of Sitafloxacin.Experimental, Investigational
Sodium phosphateSodium phosphate may increase the nephrotoxic activities of Lisofylline.Approved
SotalolLisofylline may decrease the antihypertensive activities of Sotalol.Approved
SP1049CLisofylline may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SparfloxacinLisofylline may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
SpectinomycinLisofylline may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Investigational, Vet Approved
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Lisofylline.Approved
SpironolactoneLisofylline may decrease the antihypertensive activities of Spironolactone.Approved
SRP 299The therapeutic efficacy of SRP 299 can be decreased when used in combination with Lisofylline.Investigational
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Lisofylline.Investigational
StreptomycinLisofylline may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinLisofylline may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Lisofylline.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Lisofylline.Approved
SulodexideLisofylline may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Lisofylline.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Lisofylline.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Lisofylline is combined with Suxibuzone.Experimental
TacrolimusLisofylline may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Lisofylline.Approved
TalinololLisofylline may decrease the antihypertensive activities of Talinolol.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Lisofylline.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Lisofylline.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Lisofylline.Approved
TecemotideThe therapeutic efficacy of Tecemotide can be decreased when used in combination with Lisofylline.Investigational
Technetium Tc-99m etidronateThe risk or severity of adverse effects can be increased when Lisofylline is combined with Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when Lisofylline is combined with Technetium Tc-99m medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Lisofylline.Approved, Investigational
TemafloxacinLisofylline may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Lisofylline.Experimental, Investigational
TenidapThe risk or severity of adverse effects can be increased when Lisofylline is combined with Tenidap.Experimental
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when Lisofylline is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Lisofylline.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Lisofylline.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Lisofylline.Approved
TertatololLisofylline may decrease the antihypertensive activities of Tertatolol.Experimental
TG4010The therapeutic efficacy of TG4010 can be decreased when used in combination with Lisofylline.Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Lisofylline.Approved
Tiludronic acidThe risk or severity of adverse effects can be increased when Lisofylline is combined with Tiludronic acid.Approved, Investigational, Vet Approved
TimololLisofylline may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Tinoridine.Investigational
TixocortolThe risk or severity of adverse effects can be increased when Lisofylline is combined with Tixocortol.Approved
TobramycinLisofylline may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
TofacitinibLisofylline may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Lisofylline.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Lisofylline.Approved
TorasemideLisofylline may decrease the diuretic activities of Torasemide.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Lisofylline.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Lisofylline.Approved, Investigational
TrastuzumabTrastuzumab may increase the neutropenic activities of Lisofylline.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Lisofylline.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Lisofylline.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Lisofylline is combined with Triamcinolone.Approved, Vet Approved
TriamtereneLisofylline may decrease the antihypertensive activities of Triamterene.Approved
TribenosideThe risk or severity of adverse effects can be increased when Lisofylline is combined with Tribenoside.Experimental
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Lisofylline.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Lisofylline.Investigational
TrovafloxacinLisofylline may increase the neuroexcitatory activities of Trovafloxacin.Approved, Investigational, Withdrawn
TroxerutinLisofylline may increase the anticoagulant activities of Troxerutin.Investigational
UlobetasolThe risk or severity of adverse effects can be increased when Lisofylline is combined with Ulobetasol.Approved
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Lisofylline.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Lisofylline.Investigational, Withdrawn
ValrubicinLisofylline may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Lisofylline.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Lisofylline.Approved
WarfarinLisofylline may increase the anticoagulant activities of Warfarin.Approved
XimelagatranLisofylline may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
Yellow fever vaccineThe therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Lisofylline.Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Lisofylline.Approved, Investigational
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Lisofylline.Approved, Investigational, Withdrawn
ZofenoprilThe risk or severity of adverse effects can be increased when Zofenopril is combined with Lisofylline.Experimental
Zoledronic acidThe risk or severity of adverse effects can be increased when Lisofylline is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Lisofylline.Withdrawn
Zoptarelin doxorubicinLisofylline may decrease the excretion rate of Zoptarelin doxorubicin which could result in a higher serum level.Investigational
ZorubicinLisofylline may decrease the excretion rate of Zorubicin which could result in a higher serum level.Experimental
Zoster vaccineThe therapeutic efficacy of Zoster vaccine can be decreased when used in combination with Lisofylline.Approved
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
501254
PubChem Substance
347828652
ChemSpider
438549
ChEMBL
CHEMBL1411

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1, 2CompletedNot AvailableDiabetes, Diabetes Mellitus Type 1 / Healthy Volunteers1
1, 2TerminatedBasic ScienceDiabetes, Diabetes Mellitus Type 11
2CompletedTreatmentDiabetes, Diabetes Mellitus Type 11

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility7.76 mg/mLALOGPS
logP0.78ALOGPS
logP0.2ChemAxon
logS-1.6ALOGPS
pKa (Strongest Acidic)17.68ChemAxon
pKa (Strongest Basic)-0.85ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area78.67 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity74.65 m3·mol-1ChemAxon
Polarizability30.03 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as xanthines. These are purine derivatives with a ketone group conjugated at carbons 2 and 6 of the purine moiety.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Imidazopyrimidines
Sub Class
Purines and purine derivatives
Direct Parent
Xanthines
Alternative Parents
6-oxopurines / Alkaloids and derivatives / Pyrimidones / N-substituted imidazoles / Vinylogous amides / Heteroaromatic compounds / Ureas / Secondary alcohols / Lactams / Azacyclic compounds
show 4 more
Substituents
Xanthine / 6-oxopurine / Purinone / Alkaloid or derivatives / Pyrimidone / N-substituted imidazole / Pyrimidine / Azole / Imidazole / Heteroaromatic compound
show 14 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Drug created on October 20, 2016 16:16 / Updated on November 09, 2017 05:07